{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:38:00Z","timestamp":1793835480968,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Dry eye disease (DED) is a common complication following cataract-surgery, potentially impairing visual recovery. Low-level light therapy (LLLT) has emerged as a noninvasive approach to improve ocular surface status. This study evaluated the perioperative effects of LLLT on ocular surface modulation by correlating clinical outcomes with tear biomarker dynamics and developing predictive models to identify patients most likely to benefit from LLLT. Of the 98 patients initially randomized, 88 were included in the final analysis, with 44 allocated to the LLLT group and 44 to the sham treatment group. Clinical evaluation\u2014including Ocular Surface Disease Index (OSDI) as the primary outcome, and tear breakup time, Schirmer test, and tear osmolarity as secondary endpoints\u2014was performed preoperatively and one month postoperatively to classify patients as preclinical or having DED. Tear levels of biomarkers involved in tissue repair and neurotrophic-signaling (GDF-15,\u03b2-NGF, VEGFA, PDGF-AB, PDGF-CC) and inflammation (OPN, OPG, TNF-\u03b1) were assessed as exploratory endpoints and quantified using Luminex-FlexMap3D technology. LLLT-treated patients showed significantly higher clinical improvement post-cataract surgery than sham controls (44.2% vs. 4.4%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). In DED patients, LLLT significantly increased GDF-15 (77.6\u2009\u00b1\u20097.2 to 95.5\u2009\u00b1\u20097.4 pg\/mL;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0112) and PDGF-CC (711.4\u2009\u00b1\u200976.6 to 1024\u2009\u00b1\u2009130.8 pg\/mL;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0473). The LLLT-induced \u03b2-NGF increase was more pronounced in preclinical cases than in those with baseline DED (10.1\u2009\u00b1\u20093.02 vs. 5.8\u2009\u00b1\u20090.55 pg\/mL;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0271). Biomarker profiles indicated inflammatory resolution post-LLLT, whereas sham-treated eyes showed persistent inflammation. Finally, integrative modeling of clinical and molecular data yielded a LASSO-adjusted AUC of 0.886, underscoring high discriminative performance. LLLT accelerates ocular surface recovery after cataract surgery by modulating reparative, neurotrophic, and inflammatory pathways. Tear biomarkers assessed at baseline and through one-month dynamics (GDF-15, PDGF-CC, \u03b2-NGF) and integrated with clinical parameters, may help predict treatment response and guide personalized postoperative management.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-53521-4","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:17:28Z","timestamp":1779268648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tear biomarker changes and ocular surface recovery with low-level light therapy after cataract surgery: a double-masked randomized controlled clinical trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Mihaela-Madalina","family":"Timofte-Zorila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2802-5993","authenticated-orcid":false,"given":"Mariana","family":"Pavel-Tanasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giannaccare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoleta","family":"Vlas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lixi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Troisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Tanasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Alecu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Turcas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinziana","family":"Istrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daciana Elena","family":"Branisteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Preda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Constantin","family":"Branisteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"53521_CR1","first-page":"552","volume":"29","author":"AC Day","year":"2015","unstructured":"Day, A. C., Donachie, P. H. J., Sparrow, J. M. & Johnston, R. L. The Royal College of Ophthalmologists\u2019 National Ophthalmology Database study of cataract surgery: Report 1, visual outcomes and complications. Eye (Basingstoke). 29, 552\u2013560 (2015).","journal-title":"Eye (Basingstoke)"},{"key":"53521_CR2","doi-asserted-by":"publisher","unstructured":"Naderi, K., Gormley, J. & O\u2019Brart, D. Cataract surgery and dry eye disease: A review. Eur. J. Ophthalmol. 30, 840\u2013855. https:\/\/doi.org\/10.1177\/1120672120929958 (2020) (preprint).","DOI":"10.1177\/1120672120929958"},{"key":"53521_CR3","doi-asserted-by":"publisher","unstructured":"Sutu, C., Fukuoka, H. & Afshari, N. A. Mechanisms and management of dry eye in cataract surgery patients. Curr. Opin. Ophthalmol. 27, 24\u201330. https:\/\/doi.org\/10.1097\/ICU.0000000000000227 (2016) (preprint).","DOI":"10.1097\/ICU.0000000000000227"},{"key":"53521_CR4","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.3928\/1081597X-20240514-05","volume":"40","author":"L Zhao","year":"2024","unstructured":"Zhao, L. et al. Clinical characteristic and tear film biomarkers after myopic FS-LASIK: 1-year prospective follow-up. J. Refract. Surg. 40, e508\u2013e519 (2024).","journal-title":"J. Refract. Surg."},{"key":"53521_CR5","doi-asserted-by":"publisher","unstructured":"Hamblin, M. R. Photobiomodulation or low-level laser therapy. J. Biophoton. 9, 1122\u20131124. https:\/\/doi.org\/10.1002\/jbio.201670113 (2016) (preprint).","DOI":"10.1002\/jbio.201670113"},{"key":"53521_CR6","doi-asserted-by":"publisher","unstructured":"Anders, J. J., Arany, P. R., Baxter, G. D. & Lanzafame, R. J. Light-emitting diode therapy and low-level light therapy are photobiomodulation therapy. Photobiomodul. Photomed. Laser Surg. 37, 63\u201365 . https:\/\/doi.org\/10.1089\/photob.2018.4600(2019) (preprint).","DOI":"10.1089\/photob.2018.4600"},{"key":"53521_CR7","doi-asserted-by":"publisher","unstructured":"Yadav, A. & Gupta, A. Noninvasive red and near-infrared wavelength-induced photobiomodulation: Promoting impaired cutaneous wound healing. Photodermatol. Photoimmunol. Photomed. 33, 4\u201313. https:\/\/doi.org\/10.1111\/phpp.12282 (2017) (preprint).","DOI":"10.1111\/phpp.12282"},{"key":"53521_CR8","doi-asserted-by":"publisher","unstructured":"Cannas, C. et al. Current applications and future perspectives of photobiomodulation in ocular diseases: A narrative review. Appl. Sci. (Switzerland) 14. https:\/\/doi.org\/10.3390\/app14062623 (2024) (preprint).","DOI":"10.3390\/app14062623"},{"key":"53521_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1109\/JSTQE.2016.2561201","volume":"22","author":"LF De Freitas","year":"2016","unstructured":"De Freitas, L. F. & Hamblin, M. R. Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE J. Sel. Top. Quantum Electron. 22, 348\u2013364 (2016).","journal-title":"IEEE J. Sel. Top. Quantum Electron."},{"key":"53521_CR10","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/s41433-025-03805-2","volume":"39","author":"P Viggiano","year":"2025","unstructured":"Viggiano, P., Boscia, G., Clemente, A. & Giannaccare, G. Photobiomodulation-induced choriocapillaris perfusion enhancement and outer retinal remodelling in intermediate age-related macular degeneration: A promising therapeutic approach with short-term results. Eye 39, 2057\u20132063 (2025).","journal-title":"Eye"},{"key":"53521_CR11","unstructured":"Hopewell, S. et al. CONSORT 2025 statement: Updated guideline for reporting randomised trials. BMJ 389 (2025)."},{"key":"53521_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","volume":"15","author":"JS Wolffsohn","year":"2017","unstructured":"Wolffsohn, J. S. et al. TFOS DEWS II diagnostic methodology report. Ocular Surf. 15, 539\u2013574 (2017).","journal-title":"Ocular Surf."},{"key":"53521_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ajo.2025.05.033","volume":"279","author":"JS Wolffsohn","year":"2025","unstructured":"Wolffsohn, J. S. et al. TFOS DEWS III: Diagnostic methodology. Am. J. Ophthalmol. 279, 387\u2013450 (2025).","journal-title":"Am. J. Ophthalmol."},{"key":"53521_CR14","doi-asserted-by":"crossref","unstructured":"Timofte-Zorila, M. M. et al. Novel tear biomarkers in ocular graft versus host disease associated with Th1\/Th2 immune responses: A case series and literature review. Int J. Mol. Sci 26 (2025).","DOI":"10.3390\/ijms26094311"},{"key":"53521_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cct.2018.06.002","volume":"71","author":"PA Asbell","year":"2018","unstructured":"Asbell, P. A., Maguire, M. G., Peskin, E., Bunya, V. Y. & Kuklinski, E. J. Dry eye assessment and management (DREAM\u00a9) study: Study design and baseline characteristics. Contemp. Clin. Trials. 71, 70\u201379 (2018).","journal-title":"Contemp. Clin. Trials"},{"key":"53521_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","volume":"128","author":"KL Miller","year":"2010","unstructured":"Miller, K. L. et al. Minimal clinically important difference for the ocular surface disease index. Arch. Ophthalmol. 128, 94\u2013101 (2010).","journal-title":"Arch. Ophthalmol."},{"key":"53521_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/tvst.13.7.2","volume":"13","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. GDF-15 attenuates the epithelium\u2013mesenchymal transition and alleviates TGF\u03b22-induced lens opacity. Transl Vis. Sci. Technol. 13, 2 (2024).","journal-title":"Transl Vis. Sci. Technol."},{"key":"53521_CR18","doi-asserted-by":"publisher","first-page":"30864","DOI":"10.1038\/s41598-025-16737-4","volume":"15","author":"M Fang","year":"2025","unstructured":"Fang, M. et al. Functional characteristics of fresh antitumor immune interferer GDF-15 in multiple cancers. Sci. Rep. 15, 30864 (2025).","journal-title":"Sci. Rep."},{"key":"53521_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.cytogfr.2004.09.003","volume":"15","author":"A Micera","year":"2004","unstructured":"Micera, A. et al. Nerve growth factor involvement in the visual system: Implications in allergic and neurodegenerative diseases. Cytokine Growth Factor. Rev. 15, 411\u2013417 (2004).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"53521_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1542-0124(12)70206-9","volume":"3","author":"T Nishida","year":"2005","unstructured":"Nishida, T. Neurotrophic mediators and corneal wound healing. Ocul Surf. 3, 194\u2013202 (2005).","journal-title":"Ocul Surf."},{"key":"53521_CR21","doi-asserted-by":"crossref","unstructured":"Kahuam-L\u00f3pez, N. et al. The role of nerve growth factor on the ocular surface: A review of the current experimental research and clinical practices. Int. J. Mol. Sci 26 (2025).","DOI":"10.3390\/ijms26136012"},{"key":"53521_CR22","doi-asserted-by":"crossref","unstructured":"Sacchetti, M. & Lambiase, A. Neurotrophic factors and corneal nerve regeneration. Neural Regen. Res. 12 (2017).","DOI":"10.4103\/1673-5374.213534"},{"key":"53521_CR23","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.bbapap.2012.10.015","volume":"1834","author":"PH Chen","year":"2013","unstructured":"Chen, P. H., Chen, X. & He, X. Platelet-derived growth factors and their receptors: Structural and functional perspectives. Biochim. Biophys. Acta (BBA) - Proteins Proteom. 1834, 2176\u20132186 (2013).","journal-title":"Biochim. Biophys. Acta (BBA) - Proteins Proteom."},{"key":"53521_CR24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.molmed.2013.04.006","volume":"19","author":"C Lee","year":"2013","unstructured":"Lee, C., Zhang, F., Tang, Z., Liu, Y. & Li, X. PDGF-C: A new performer in the neurovascular interplay. Trends Mol. Med. 19, 474\u2013486 (2013).","journal-title":"Trends Mol. Med."},{"key":"53521_CR25","doi-asserted-by":"crossref","unstructured":"Li, X. et al. VEGF-independent angiogenic pathways induced by PDGF-C. Oncotarget 1. www.impactjournals.com\/oncotarget\/www.impactjournals.com\/oncotarget (2010).","DOI":"10.18632\/oncotarget.141"},{"key":"53521_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1542-0124(12)70613-4","volume":"5","author":"B Klenkler","year":"2007","unstructured":"Klenkler, B., Sheardown, H. & Jones, L. Growth factors in the tear film: Role in tissue maintenance, wound healing, and ocular pathology. Ocul Surf. 5, 228\u2013239 (2007).","journal-title":"Ocul Surf."},{"key":"53521_CR27","doi-asserted-by":"crossref","unstructured":"Zhao, Y. et al. Corneal subbasal nerve alterations and tear cytokine associations in ocular chronic graft-versus-host disease. Front Med. (Lausanne) 12 (2025).","DOI":"10.3389\/fmed.2025.1662302"},{"key":"53521_CR28","doi-asserted-by":"publisher","unstructured":"Hock, J. M., Raisz, L. G. & Canalis, E. Parathyroid hormone. Parathyroids. 183\u2013198. https:\/\/doi.org\/10.1016\/B978-012098651-4\/50013-4 (2001).","DOI":"10.1016\/B978-012098651-4\/50013-4"},{"key":"53521_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.knee.2008.08.008","volume":"16","author":"NS Tumia","year":"2009","unstructured":"Tumia, N. S. & Johnstone, A. J. Platelet derived growth factor-AB enhances knee meniscal cell activity in vitro. Knee 16, 73\u201376 (2009).","journal-title":"Knee"},{"key":"53521_CR30","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1056\/NEJMcibr050670","volume":"352","author":"S Dimmeler","year":"2005","unstructured":"Dimmeler, S. Platelet-derived growth factor CC \u2014 A clinically useful angiogenic factor at last? N. Engl. J. Med. 352, 1815\u20131816 (2005).","journal-title":"N. Engl. J. Med."},{"key":"53521_CR31","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez, C. E. & Smith, P. C. & Palma Alvarado, V. A. The influence of platelet-derived products on angiogenesis and tissue repair: A concise update. Front. Physiol. 6, 2015 (2015).","DOI":"10.3389\/fphys.2015.00290"},{"key":"53521_CR32","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/opo.13371","volume":"44","author":"A Antwi","year":"2024","unstructured":"Antwi, A., Schill, A. W., Redfern, R. & Ritchey, E. R. Effect of low-level light therapy in individuals with dry eye disease. Ophthalmic Physiol. Opt. 44, 1464\u20131471 (2024).","journal-title":"Ophthalmic Physiol. Opt."},{"key":"53521_CR33","doi-asserted-by":"crossref","unstructured":"Lang, F., Li, Y., Yao, R. & Jiang, M. Osteopontin in chronic inflammatory diseases: Mechanisms, biomarker potential, and therapeutic strategies. Biology (Basel) 14 (2025).","DOI":"10.3390\/biology14040428"},{"key":"53521_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12079-009-0068-0","volume":"3","author":"SA Lund","year":"2009","unstructured":"Lund, S. A., Giachelli, C. M. & Scatena, M. The role of osteopontin in inflammatory processes. J. Cell. Commun. Signal. 3, 311\u2013322 (2009).","journal-title":"J. Cell. Commun. Signal."},{"key":"53521_CR35","doi-asserted-by":"crossref","unstructured":"Kim, J. et al. Osteopontin is a biomarker for early autoimmune uveoretinitis. Neural Regen. Res. 17 (2022).","DOI":"10.4103\/1673-5374.330614"},{"key":"53521_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1084\/jem.20071412","volume":"205","author":"R Mori","year":"2008","unstructured":"Mori, R., Shaw, T. J. & Martin, P. Molecular mechanisms linking wound inflammation and fibrosis: Knockdown of osteopontin leads to rapid repair and reduced scarring. J. Exp. Med. 205, 43\u201351 (2008).","journal-title":"J. Exp. Med."},{"key":"53521_CR37","doi-asserted-by":"publisher","first-page":"18946","DOI":"10.1038\/s41598-021-98177-4","volume":"11","author":"M Dekker","year":"2021","unstructured":"Dekker, M. et al. High levels of osteoprotegerin are associated with coronary artery calcification in patients suspected of a chronic coronary syndrome. Sci. Rep. 11, 18946 (2021).","journal-title":"Sci. Rep."},{"key":"53521_CR38","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1161\/ATVBAHA.110.208843","volume":"30","author":"K Caidahl","year":"2010","unstructured":"Caidahl, K., Ueland, T. & Aukrust, P. Osteoprotegerin: A biomarker with many faces. Arterioscler. Thromb. Vasc Biol. 30, 1684\u20131686 (2010).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"53521_CR39","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41574-020-00428-3","volume":"16","author":"C Greenhill","year":"2020","unstructured":"Greenhill, C. Osteoprotegerin sources examined. Nat. Rev. Endocrinol. 16, 678 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"53521_CR40","doi-asserted-by":"publisher","unstructured":"Walsh, M. C. & Choi, Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front. Immunol. 5. https:\/\/doi.org\/10.3389\/fimmu.2014.00511 (2014) (preprint).","DOI":"10.3389\/fimmu.2014.00511"},{"key":"53521_CR41","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1091\/mbc.e04-01-0059","volume":"15","author":"LB Pritzker","year":"2004","unstructured":"Pritzker, L. B., Scatena, M. & Giachelli, C. M. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol. Biol. Cell. 15, 2834\u20132841 (2004).","journal-title":"Mol. Biol. Cell."},{"key":"53521_CR42","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/j.1538-7836.2011.04207.x","volume":"9","author":"Z Benslimane-Ahmim","year":"2011","unstructured":"Benslimane-Ahmim, Z. et al. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. J. Thromb. Haemost. 9, 834\u2013843 (2011).","journal-title":"J. Thromb. Haemost."},{"key":"53521_CR43","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1167\/iovs.16-20993","volume":"58","author":"AM Abu El-Asrar","year":"2017","unstructured":"Abu El-Asrar, A. M. et al. Osteoprotegerin is a new regulator of inflammation and angiogenesis in proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 58, 3189\u20133201 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"53521_CR44","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1080\/09273948.2017.1343855","volume":"26","author":"AM Abu El-Asrar","year":"2018","unstructured":"Abu El-Asrar, A. M. et al. Unbalanced vitreous levels of osteoprotegerin, RANKL, RANK, and TRAIL in proliferative diabetic retinopathy. Ocul Immunol. Inflamm. 26, 1248\u20131260 (2018).","journal-title":"Ocul Immunol. Inflamm."},{"key":"53521_CR45","doi-asserted-by":"crossref","unstructured":"Martinez-Gutierrez, A. et al. Hyaluronic and succinic acid: New biostimulating combination to counteract dermal and subcutaneous aging. Int. J. Mol. Sci. 26 (2025).","DOI":"10.3390\/ijms26157548"},{"key":"53521_CR46","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jtos.2019.08.004","volume":"17","author":"T Panigrahi","year":"2019","unstructured":"Panigrahi, T. et al. Trehalose augments autophagy to mitigate stress induced inflammation in human corneal cells. Ocular Surf. 17, 699\u2013713 (2019).","journal-title":"Ocular Surf."},{"key":"53521_CR47","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s40123-025-01228-6","volume":"14","author":"MM Timofte-Zorila","year":"2025","unstructured":"Timofte-Zorila, M. M. et al. Effect of low-level light therapy on ocular surface parameters in patients undergoing cataract surgery: A prospective double-masked randomized controlled clinical trial. Ophthalmol. Ther. 14, 2557\u20132569 (2025).","journal-title":"Ophthalmol. Ther."},{"key":"53521_CR48","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1136\/bjo-2023-323920","volume":"108","author":"G Giannaccare","year":"2024","unstructured":"Giannaccare, G. et al. Outcomes of low-level light therapy before and after cataract surgery for the prophylaxis of postoperative dry eye: a prospective randomised double-masked controlled clinical trial. Br. J. Ophthalmol. 108, 1172 (2024).","journal-title":"Br. J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53521-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:28:40Z","timestamp":1784759320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53521-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53521"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53521-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol complied with the Declaration of Helsinki and was approved by the local Ethics Committee of the\n                      Cai Ferate\n                      Clinical Hospital in Ia\u0219i, Romania (approval number: 54\/29.07.2024). It was retrospectively registered at ClinicalTrials.gov (NCT07067294) on 05.07.2025, and all patients provided written informed consent.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22977"}}